These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 23355631)

  • 21. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease.
    Mulder C; Verwey NA; van der Flier WM; Bouwman FH; Kok A; van Elk EJ; Scheltens P; Blankenstein MA
    Clin Chem; 2010 Feb; 56(2):248-53. PubMed ID: 19833838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury.
    Blennow K; Nellgård B
    Neurology; 2004 Jan; 62(1):159; author reply 159-60. PubMed ID: 14718730
    [No Abstract]   [Full Text] [Related]  

  • 23. [Searched for and found: non-demented patients with Alzheimer's disease].
    Engelborghs S
    Tijdschr Psychiatr; 2011; 53(9):654-6. PubMed ID: 21898323
    [No Abstract]   [Full Text] [Related]  

  • 24. Interactions between amyloid-β and tau in cerebrospinal fluid of people with mild cognitive impairment and Alzheimer's disease.
    Kristofikova Z; Ricny J; Kolarova M; Vyhnalek M; Hort J; Laczo J; Sirova J; Ripova D
    J Alzheimers Dis; 2014; 42 Suppl 3():S91-8. PubMed ID: 24670397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of florbetaben PET imaging and the amyloid peptide Aß42 in cerebrospinal fluid.
    Schipke CG; Koglin N; Bullich S; Joachim LK; Haas B; Seibyl J; Barthel H; Sabri O; Peters O
    Psychiatry Res Neuroimaging; 2017 Jul; 265():98-101. PubMed ID: 28024844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation and Clinical Utility of ELISA Methods for Quantification of Amyloid-β of Peptides in Cerebrospinal Fluid Specimens from Alzheimer’s Disease Studies.
    Lachno DR; Evert BA; Maloney K; Willis BA; Talbot JA; Vandijck M; Dean RA
    J Alzheimers Dis; 2015; 45(2):527-42. PubMed ID: 25547638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.
    Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S
    J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias.
    Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Otto M; Kornhuber J; Rüther E; Wiltfang J
    Dement Geriatr Cogn Disord; 2011; 31(1):37-44. PubMed ID: 21135556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reference measurement procedure for CSF amyloid beta (Aβ)
    Pannee J; Portelius E; Minthon L; Gobom J; Andreasson U; Zetterberg H; Hansson O; Blennow K
    J Neurochem; 2016 Nov; 139(4):651-658. PubMed ID: 27579672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ38, Aβ40, and Aβ42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls.
    Pannee J; Portelius E; Oppermann M; Atkins A; Hornshaw M; Zegers I; Höjrup P; Minthon L; Hansson O; Zetterberg H; Blennow K; Gobom J
    J Alzheimers Dis; 2013; 33(4):1021-32. PubMed ID: 23076076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid.
    Kruse N; Schlossmacher MG; Schulz-Schaeffer WJ; Vanmechelen E; Vanderstichele H; El-Agnaf OM; Mollenhauer B
    PLoS One; 2016; 11(4):e0153564. PubMed ID: 27116005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and validation of dried matrix spot sampling for the quantitative determination of amyloid β peptides in cerebrospinal fluid.
    Delaby C; Gabelle A; Meynier P; Loubiere V; Vialaret J; Tiers L; Ducos J; Hirtz C; Lehmann S
    Clin Chem Lab Med; 2014 May; 52(5):649-55. PubMed ID: 24150208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.
    Olsson A; Vanderstichele H; Andreasen N; De Meyer G; Wallin A; Holmberg B; Rosengren L; Vanmechelen E; Blennow K
    Clin Chem; 2005 Feb; 51(2):336-45. PubMed ID: 15563479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tapping into the biology of Alzheimer disease.
    Knopman DS
    Neurology; 2011 Feb; 76(6):496-7. PubMed ID: 21228299
    [No Abstract]   [Full Text] [Related]  

  • 35. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
    Williams SM; Schulz P; Sierks MR
    Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.
    Molinuevo JL; Blennow K; Dubois B; Engelborghs S; Lewczuk P; Perret-Liaudet A; Teunissen CE; Parnetti L
    Alzheimers Dement; 2014 Nov; 10(6):808-17. PubMed ID: 25150736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients.
    Fukuyama R; Mizuno T; Mori S; Nakajima K; Fushiki S; Yanagisawa K
    Eur Neurol; 2000; 43(3):155-60. PubMed ID: 10765056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amyloid beta protein species in cerebrospinal fluid and in brain from patients with Down's syndrome.
    Tamaoka A; Sekijima Y; Matsuno S; Tokuda T; Shoji S; Ikeda SI
    Ann Neurol; 1999 Dec; 46(6):933. PubMed ID: 10589550
    [No Abstract]   [Full Text] [Related]  

  • 39. Lumbar drains can affect CSF biomarker levels.
    Craven CL; Chapman MD; D'Antona L; Thompson SD; Lakdawala N; Zetterberg H; Watkins LD; Toma AK
    J Clin Pathol; 2019 Jan; 72(1):91-92. PubMed ID: 29997233
    [No Abstract]   [Full Text] [Related]  

  • 40. Differences and similarities between two frequently used assays for amyloid beta 42 in cerebrospinal fluid.
    Schoonenboom NS; Mulder C; Vanderstichele H; Pijnenburg YA; Van Kamp GJ; Scheltens P; Mehta PD; Blankenstein MA
    Clin Chem; 2005 Jun; 51(6):1057-60. PubMed ID: 15845801
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.